First Patient Treated in Rakuten Medical's Global Phase 3 Trial in India devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
Rakuten Medical, a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization CDSCO to conduct its global, pivotal Phase 3 clinical trial ASP-1929-301ClinicalTrials.gov Identifier NCT03769506 evaluating Alluminox treatment photoimmunotherapy using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas HNSCC in India, and the registration of clinical trial information with the Clinical Trial Registry of India CTRI has been completed CTRI Identifier CTRI202305052728.